The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer.
5,6-Dimethylxanthenone-4-acetic acid (DMXAA) is a vascular disrupting agent that has demonstrated efficacy in combination with taxane-based chemotherapy in patients with advanced cancer. Complementary modes of action, a lack of pharmacokinetic interaction and distinct adverse effect profiles provide a strong rationale for combining these anticancer agents. In a Phase II trial in men with hormone refractory prostate cancer, DMXAA (ASA404) in combination with docetaxel achieved a prostate-specific antigen response in more patients than docetaxel therapy alone, and was generally well tolerated. Further clinical evaluation of this combination in this patient population is warranted.
McKeage
Mark J
MJ
The University of Auckland, School of Medical Sciences, Department of Pharmacology and Clinical Pharmacology, Private Bag 92019, Auckland, New Zealand. m.mckeage@auckland.ac.nz
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D018572:Disease-Free Survival; D000077143:Docetaxel; D006801:Humans; D008297:Male; D009361:Neoplasm Invasiveness; D017430:Prostate-Specific Antigen / Q000032:analysis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D044004:Xanthones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
D043823:Taxoids; D044004:Xanthones; C066668:vadimezan; D000077143:Docetaxel; D017430:Prostate-Specific Antigen